Recombinant DNA Tech boosts healthcare with therapeutic proteins, vaccines & gene therapies for chronic diseases. The $4.27 trillion recombinant DNA technology market is propelled by pharma giants ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, has entered a collaboration with German biotechnology company Cilian AG to develop a solid ...

Endotoxin testing is critical for quality control in drug production, as it has a direct impact on pharmaceutical safety and effectiveness. Traditionally Limulus Amebocyte Lysate (LAL) testing is used ...